BMC Cancer

CORRECTION Open Access

Correction to: Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM

Lina Mörén[1], Richard Perryman[2], Tim Crook[3], Julia K. Langer[2], Kevin Oneill[2], Nelofer Syed[2*] and Henrik Antti[1*]

Correction

In the original publication of this article [1], published on 8 February 2018, it was noticed that the acknowledgement of the source of the drug ADI-PEG20 was missing. In this Correction, the source of drug ADI-PEG20 is shown (and marked bold). This addition is made in the Methods section, under the heading ADI-PEG20 treatment.

ADI-PEG20 treatment.

SNB19 and U87 cells, cultured in DMEM + 10% FBS and normal human astrocytes, cultured in speciality media provided by lonza were seeded in replicates (n = 12) at 8 × 104 cells per well in 6-well dishes (Corning, NY, USA). 24 h post seeding, cells were washed with phosphate buffered saline (PBS) and cultured in the presence or absence of ADI-PEG20 **(kindly provided by Polaris Pharmaceuticals Inc, San Diego, CA)** (1 μg/ml) in media containing, 1 mM citrulline and 10% fetal FBS. ADI-PEG20 was added at the start of the experiment and no fresh media was added to any of the experimental plates before harvesting. ADI-PEG20 treated and untreated media (n = 3) was included for normalization purposes. 48 h after ADI-PEG20 treatment replicate samples for each condition (n = 3) were harvested, collecting both spent media and cells for GC-TOFMS metabolomic analysis. Additional replicates (n = 3) of each condition were collected for total cell count determination.

Author details
[1]Department of Chemistry, Umeå University, SE 901 87 Umeå, Sweden. [2]John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK. [3]St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK.

Received: 13 February 2018 Accepted: 13 February 2018
Published online: 08 March 2018

Reference
1. Mörén L, et al. Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM. BMC Cancer. 2018;18:167. https://doi.org/10.1186/s12885-018-4040-3.

* Correspondence: n.syed@imperial.ac.uk; henrik.antti@umu.se
[2]John Fulcher Neuro-Oncology Laboratory, Imperial College London, London, UK
[1]Department of Chemistry, Umeå University, SE 901 87 Umeå, Sweden
Full list of author information is available at the end of the article